Trial reportClinical journal of the American Society of Nephrology : CJASN2011
Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- Predictors of autosomal dominant polycystic kidney disease progression.Journal of the American Society of Nephrology : JASN · 2014Pooled it
- Bioactive lipid mediators in polycystic kidney disease.Journal of lipid research · 2014Trial
- Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2014Trial
- Cardio-Thoracic Ratio for Detecting Left Ventricular Hypertrophy on Abdominal MRI in ADPKD.Journal of magnetic resonance imaging : JMRI · 2026Article
- Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.Renal failure · 2025Review
- Determinants of left ventricular mass in children with autosomal recessive polycystic kidney disease.Journal of nephrology · 2025Article
- Cardiac complications in autosomal dominant polycystic kidney disease: links to genotype and CKD severity.Clinical kidney journal · 2025Article
- Cardiovascular Manifestations and Management in ADPKD.Kidney international reports · 2023Review
- Renal Insufficiency Increases the Combined Risk of Left Ventricular Hypertrophy and Dysfunction in Patients at High Risk of Cardiovascular Diseases.Journal of clinical medicine · 2023Article
- Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients.Journal of clinical medicine · 2022Article
- A Systematic Review of Reported Outcomes in ADPKD Studies.Kidney international reports · 2022Article
- Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD.Kidney international reports · 2022Article
- Polycystins, ADPKD, and Cardiovascular Disease.Kidney international reports · 2020Review
- Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.BMC nephrology · 2019Article
- Cardiac function assessed by myocardial deformation in adult polycystic kidney disease patients.BMC nephrology · 2019Article
- Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?Pediatric nephrology (Berlin, Germany) · 2019Article
- Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.Kidney international reports · 2018Article
- Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.Cardiorenal medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesAutosomal dominant polycystic kidney disease (ADPKD) is associated with a substantial cardiovascular disease burden including early onset hypertension, intracranial aneurysms, and left ventricular hypertrophy (LVH). A 41% prevalence of LVH has been reported in ADPKD, using echocardiographic assessment of LV mass (LVM). The HALT PKD study was designed to assess the effect of intensive angiotensin blockade on progression of total kidney volume and LVM. Measurements of LVM were performed using cardiac magnetic resonance (MR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five hundred forty-three hypertensive patients with GFR >60 ml/min per 1.73 m(2) underwent MR assessment of LVM at baseline. LVM was adjusted for body surface area and expressed as LVM index (LVMI; g/m(2)).
resultsBaseline BP was 125.1 ± 14.5/79.3 ± 11.6 mmHg. Average duration of hypertension was 5.79 years. Prior use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was present in 59.5% of patients. The prevalence of LVH assessed using nonindexed LVM (g) was 3.9% (n = 21, eight men and 13 women) and 0.93% (n = 5, one man and four women) using LVMI (g/m(2)). In exploratory analyses, the prevalence of LVH using LVM indexed to H(2.7), and the allometric index ppLVmass(HW), ranged from 0.74% to 2.23% (n = 4 to 12). Multivariate regression showed significant direct associations of LVMI with systolic BP, serum creatinine, and albuminuria; significant inverse associations with LVMI were found with age and female gender.
conclusionsThe prevalence of LVH in hypertensive ADPKD patients <50 years of age with short duration of hypertension, and prior use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is low. Early BP intervention in ADPKD may have decreased LVH and may potentially decrease cardiovascular mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.